Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers in Clozapine-responding Schizophrenia
2019-003128-19Phase 4Active
- Sponsor
- Psykiatrisk Center Glostrup
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clozapine in schizophrenia, Schizophrenia Spectrum Disorders (SSD), schizoaffective disorder and 1 more, sponsored by Psykiatrisk Center Glostrup. Primary endpoint: Permeability of the blood-brain barrier. Started Aug 2019; status: active.
02
Drugs
clozapine
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)schizoaffective disorderother nonorganic psychotic disorder
Beyond the preview
Go deeper on 2019-003128-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003128-19.